Dermatology News and Research

Latest Dermatology News and Research

Warner Chilcott to acquire U.S. rights to Enablex from Novartis for $400 million

Warner Chilcott plc today announced that it has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex® from Novartis for $400 million in cash. Enablex (darifenacin) is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales of approximately $190 million for the year ended December 31, 2009.

24 Sep 2010

Researchers discover molecular signature to predict TB infection

Dallas scientists recently discovered a molecular signature in the blood of patients with tuberculosis (TB) that may explain why some people develop an active TB infection, while others exposed to the bacteria which causes the dangerous respiratory virus do not.

24 Sep 2010

NextGen Healthcare becomes CCHIT Certified for Dermatology and Behavioral Health

NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, today announced that NextGen® Ambulatory EHR version 5.6, a CCHIT Certified® 2011 Ambulatory EHR, has been additionally certified for Dermatology and Behavioral Health in the Certification Commission for Health Information Technology's (CCHIT®) certification program.

23 Sep 2010

Scientists develop new therapy for treatment of skin, lung cancer

Scientists at the University of Granada have developed a new therapy for the treatment of skin and lung cancer. This therapy involves the use of a suicide coliphage-gene (gene E) that can induce death to cells transfected with it.. Their studies have demostrated that this technique is not only effective in vitro (using tumour cell cultures), but also in vivo through the use of experimental animals in which tumours were induced.

22 Sep 2010

Valeant prices offering of senior unsecured notes

Valeant Pharmaceuticals International announced today that it has priced its previously announced offering of senior unsecured notes, which consists of $500 million of 6.75% Senior Notes due 2017 and $700 million of 7.00% Senior Notes due 2020 (collectively, the "Notes"). The $1.2 billion combined aggregate principal amount of the Notes was increased from the previously announced offering size of $1.0 billion. The offering is expected to close on or about September 28, 2010.

22 Sep 2010

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Apricus Biosciences, backed by a revenue-generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical requirements for assessing the approvability of RayVa for the treatment of Raynaud's syndrome secondary to scleroderma.

22 Sep 2010

Sun Pharma completes acquisition of controlling stake in Taro

Sun Pharmaceutical Industries Ltd. today announced that it has completed the acquisition of a controlling stake in Taro Pharmaceutical Industries Ltd. pursuant to the Option Agreement entered into in 2007 with Taro's controlling shareholders led by Taro's Chairman, Dr. Barrie Levitt.

22 Sep 2010

USP PET results qualify Apricus Bio's NexACT as anti-microbial preservative

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that results from a United States Pharmacopeia Preservative Efficacy Test (USP PET) qualified NexACT as an anti-microbial preservative. The results show that NexACT was effective in killing more than 23 strains of bacteria, fungus and mold, well beyond the requirements for passing the USP PET.

21 Sep 2010

Solta Medical's Fraxel re:store Dual system for actinic keratosis receives FDA 510(k) clearance

Solta Medical, Inc., the pioneer in fractional resurfacing and non-invasive skin tightening and a market leader in aesthetic skin treatments, today announced it has received FDA 510(k) clearance of its Fraxel re:store®Dual for the treatment of actinic keratosis (AKs). The Fraxel re:store Dual system takes the industry leading fractional laser technology to the next level by adding a novel 1927 nm wavelength, the first ever application of a Thulium laser in the aesthetics market.

17 Sep 2010

Severe acne linked to suicidal thoughts in teenagers

According to a new study on Norwegian youth, compared to clear-skinned peers, teens who have bad acne are more than twice as likely to have mental health problems and are at greater risk of having suicidal thoughts.

16 Sep 2010

Study reveals men less likely to use active sun-protective measures

There is a significant disparity between knowledge and attitudes on the dangers of skin cancer among male and female medical students in Florida according to a new study by a joint team of researchers from Ben-Gurion University of the Negev and the University of Miami Miller School of Medicine. The study was published in the American Medical Association's Archives of Dermatology.

15 Sep 2010

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.

15 Sep 2010

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced results from a pre-clinical pharmacokinetic study showing the ability of NexACT to enable rectal delivery of biologics, such as human antibodies.

15 Sep 2010

Cetaphil launches Restoraderm for management of eczema and atopic dermatitis skin

The Cetaphil® brand, the #1 dermatologist-recommended brand of cleansers and moisturizers announced the launch of Cetaphil® Restoraderm® products, formulated specifically for the needs of eczema and atopic dermatitis skin. Cetaphil® Restoraderm® Skin Restoring Body Wash and Skin Restoring Moisturizer soothes itching associated with skin affected by eczema and atopic dermatitis.

14 Sep 2010

Researchers focus on finding markers to detect atypical vascular lesions that lead to angiosarcomato

Physicians have long noticed that breast cancer patients who have had surgery or radiation therapy have an heightened risk of developing angiosarcoma, a rare type of cancer that originates in the lining of the blood vessels.

14 Sep 2010

IGI submits first ANDA to FDA

IGI Laboratories, Inc., a New Jersey based formulation and manufacturing company, today announced that it has submitted its first abbreviated new drug application (ANDA) to the US FDA. IGI President and CEO Charlie Moore commented "This is a significant step forward in validating IGI's commitment to pharmaceutical product development.

14 Sep 2010

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 7th International Melanoma Research Congress in Sydney, Australia, on November 4, 2010 at 4:30 p.m., as part of the 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting,

13 Sep 2010

Researchers to develop image analysis techniques for melanoma classification

Melanoma, the most serious form of skin cancer varies in size, shape and severity, and although pathologists and researchers often intuitively differentiate between types of melanomas, the variations have never been formally quantified and documented. A project involving RENCI and researchers in the University of North Carolina School of Medicine and the departments of computer science and statistics and operations research aims to change that by using image analysis techniques to improve melanoma classification.

10 Sep 2010

Halozyme Therapeutics announces public offering of 8.3 million shares of common stock

Halozyme Therapeutics, Inc. today announced the pricing of its previously announced public offering of 8.3 million shares of its common stock at a price to the public of $7.50 per share.

10 Sep 2010

Halozyme Therapeutics offers to sell 8.3 million shares of common stock

Halozyme Therapeutics, Inc. today announced that it is offering to sell 8.3 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering

9 Sep 2010

Dermatology News and Research

Latest Dermatology News and Research

Warner Chilcott to acquire U.S. rights to Enablex from Novartis for $400 million

Researchers discover molecular signature to predict TB infection

NextGen Healthcare becomes CCHIT Certified for Dermatology and Behavioral Health

Scientists develop new therapy for treatment of skin, lung cancer

Valeant prices offering of senior unsecured notes

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Sun Pharma completes acquisition of controlling stake in Taro

USP PET results qualify Apricus Bio's NexACT as anti-microbial preservative

Solta Medical's Fraxel re:store Dual system for actinic keratosis receives FDA 510(k) clearance

Severe acne linked to suicidal thoughts in teenagers

Study reveals men less likely to use active sun-protective measures

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

Cetaphil launches Restoraderm for management of eczema and atopic dermatitis skin

Researchers focus on finding markers to detect atypical vascular lesions that lead to angiosarcomato

IGI submits first ANDA to FDA

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Researchers to develop image analysis techniques for melanoma classification

Halozyme Therapeutics announces public offering of 8.3 million shares of common stock

Halozyme Therapeutics offers to sell 8.3 million shares of common stock

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dermatology News and Research

Latest Dermatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in